Selinexor Overcomes Hypoxia-Induced Drug Resistance in Multiple Myeloma
Sign Up to like & getrecommendations! Published in 2017 at "Translational Oncology"
DOI: 10.1016/j.tranon.2017.04.010
Abstract: Increased levels of the nuclear export protein, exportin 1 (XPO1), were demonstrated in multiple myeloma (MM) patients. Targeting XPO1 with selinexor (the selective inhibitor of nuclear export; SINE compound KPT-330) demonstrates broad antitumor activity also… read more here.
Keywords: drug resistance; multiple myeloma; resistance; selinexor ... See more keywords
A drug profile on selinexor for the treatment of refractory diffuse large B-cell lymphoma
Sign Up to like & getrecommendations! Published in 2022 at "Expert Review of Hematology"
DOI: 10.1080/17474086.2022.2057295
Abstract: ABSTRACT Introduction The efficacy of selinexor, the first commercially available exportin inhibitor, has been evaluated in patients with diffuse large B-cell lymphoma (DLBCL) who have received at least 2 lines of therapy. Its role in… read more here.
Keywords: cell lymphoma; large cell; diffuse large; selinexor treatment ... See more keywords
PL3.5 Efficacy and safety of selinexor in recurrent glioblastoma
Sign Up to like & getrecommendations! Published in 2019 at "Neuro-Oncology"
DOI: 10.1093/neuonc/noz126.008
Abstract: New treatment modalities are needed for recurrent glioblastoma (rGBM). Selinexor is a novel, oral selective inhibitor of nuclear export which forces nuclear retention of tumor suppressor proteins including p53 and p27, leading to apoptosis. We… read more here.
Keywords: efficacy safety; efficacy; selinexor; recurrent glioblastoma ... See more keywords
Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia
Sign Up to like & getrecommendations! Published in 2019 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-19-2169
Abstract: Purpose: Induction chemotherapy results in complete remission (CR) rates of 20% to 50% among patients with poor-risk AML. Selinexor is an oral selective inhibitor of nuclear export with promising single-agent activity. By inhibiting the primary… read more here.
Keywords: clinical trial; risk; selinexor; phase ... See more keywords
Abstract 464: Novel role of xpo1 in regulating MicroRNAs related to pancreatic ductal adenocarcinoma invasion and metastasis
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Research"
DOI: 10.1158/1538-7445.am2017-464
Abstract: Objective: There are no known reports on the role of exportin 1 (XPO1; also known as chromosome maintenance region 1 [CRM1]) in microRNA biology. In this study, we for the first time demonstrate that interfering… read more here.
Keywords: ductal adenocarcinoma; mir 145; invasion; pancreatic ductal ... See more keywords
Selinexor: A First-in-Class Nuclear Export Inhibitor for Management of Multiply Relapsed Multiple Myeloma
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Pharmacotherapy"
DOI: 10.1177/1060028019892643
Abstract: Objective: To review the pharmacology, pharmacokinetics, efficacy, and safety of selinexor for management of relapsed multiple myeloma (MM). Data Sources: A literature search was performed of PubMed and MEDLINE databases (January 1, 2000, to November… read more here.
Keywords: selinexor first; relapsed multiple; management; multiple myeloma ... See more keywords
SIENDO/ENGOT-EN5/GOG-3055: A randomized phase 3 trial of maintenance selinexor versus placebo after combination platinum-based chemotherapy in advanced or recurrent endometrial cancer.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.tps5610
Abstract: TPS5610 Background: Endometrial cancer (EC) is the most common gynecologic malignancy. Options for advanced or recurrent EC following platinum-based therapy and/or radiotherapy are limited and prognosis remains poor. Selinexor is a novel, oral selective inhibitor… read more here.
Keywords: therapy; maintenance; advanced recurrent; disease ... See more keywords
Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.21.01829
Abstract: PURPOSE Antitumor activity in preclinical models and a phase I study of patients with dedifferentiated liposarcoma (DD-LPS) was observed with selinexor. We evaluated the clinical benefit of selinexor in patients with previously treated DD-LPS whose… read more here.
Keywords: dedifferentiated liposarcoma; randomized double; double blind; placebo ... See more keywords
The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL Study
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14030791
Abstract: Simple Summary Diffuse large B-cell lymphoma (DLBCL) is a complex disease. A combination of immunotherapy and chemotherapy is used to treat DLBCL at initial diagnosis. Additional treatments are available when DLBCL does not respond to… read more here.
Keywords: cell lymphoma; large cell; diffuse large; selinexor ... See more keywords